FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to an antigen receptor containing a GITRL domain on the C-terminal side through a self-splitting peptide domain, as well as to a polynucleotide coding said antigen receptor. Also disclosed is a cell expressing said antigen receptor, wherein the cell is a T-cell with cytotoxic activity or NK-cell, and a pharmaceutical composition.
EFFECT: invention provides creation of antigen receptor with high therapeutic or preventive effect on cancer.
11 cl, 23 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GD2 BINDING MOLECULE | 2020 |
|
RU2824670C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| CHIMERIC ANTIGEN RECEPTORS | 2015 |
|
RU2745705C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2729118C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| CELL | 2015 |
|
RU2768019C2 |
| CELL | 2014 |
|
RU2717984C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| CELL | 2014 |
|
RU2732236C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
